Compugen Strikes $500m Research Pact With Bayer

The two will develop cancer treatments using Israeli firm’s technology.

Shares of Compugen spiked by more than 60% in trading on the Tel Aviv Stock Exchange Monday, after the Israeli drug discovery company signed a licensing and collaboration agreement with Bayer HealthCare that could be worth more than $500 million.